15 June 2022 - HIRA has been analysing how new reimbursements for anti-diabetic combination therapies mixing oral SGLT-2 and DPP-4 inhibitors would affect the national health insurance financing.

If the national health insurance covers SGLT-2 inhibitors in combination with DPP-4 inhibitors, which are used for a broad diabetic population, it will significantly increase government spending on health insurance.

Read Korea Biomedical Review article